Description
Reg. No. G4292 (Act 36/1947)
Namibia Reg. No. V19/18.3.10/1441 [NS0]
INDICATIONS
For the treatment and prevention of tick, flea and mite infestations in dogs and cats.
Bravecto® Spot-On can be used as part of a treatment strategy for Flea Allergy Dermatitis (FAD). For the treatment of mange caused by Demodex spp. and Sarcoptes scabiei mites in dogs. For the treatment of Otodectes spp. mite infestations in dogs and cats.
In cats, Bravecto® Spot-On provides immediate and persistent flea and tick killing activity for 3 months.
In dogs, Bravecto® Spot-On provides immediate and persistent tick killing activity for 4 months and flea killing activity for 6 months. Bravecto® Spot-On is well tolerated in MDR1 dogs.
A single treatment prevents Dipylidium caninum transmission from infected fleas to susceptible dogs for 12 weeks.
COMPOSITION
Each 1 mℓ of Bravecto® Spot-On contains 280 mg fluralaner.
Each pipette delivers:
| Miniature dogs: | 112,5 mg fluralaner | Small cats: | 112,5 mg fluralaner |
| Small dogs: | 250 mg fluralaner | Medium cats: | 250 mg fluralaner |
| Medium dogs: | 500 mg fluralaner | Large cats: | 500 mg fluralaner |
| Large dogs: | 1 000 mg fluralaner | ||
| Extra-large dogs: | 1 400 mg fluralaner |
CLINICAL PHARMACOLOGY
Peak fluralaner concentrations are achieved between 7 and 42 days following topical administration and the elimination half-life ranges between 14 and 29 days. The bioavailability of fluralaner following oral and topical administration is approximately 25 %.
PHARMACODYNAMIC PROPERTIES
Fluralaner is an acaricide and insecticide. It is efficacious against ticks, fleas and mites.
Fluralaner is for systemic use and belongs to the class of isoxazoline-substituted benzamide derivatives.
Fluralaner is an inhibitor of parts of the arthropod nervous system. The mode of action of fluralaner is the antagonism of the ligand-gated chloride channels (gamma-aminobutyric acid (GABA)-receptor and glutamate-receptor).
